NASDAQ:NRIX Nurix Therapeutics Q4 2025 Earnings Report $23.81 +0.14 (+0.59%) As of 03:14 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Nurix Therapeutics EPS ResultsActual EPS-$0.82Consensus EPS -$0.84Beat/MissBeat by +$0.02One Year Ago EPSN/ANurix Therapeutics Revenue ResultsActual Revenue$13.58 millionExpected Revenue$13.41 millionBeat/MissBeat by +$163.00 thousandYoY Revenue GrowthN/ANurix Therapeutics Announcement DetailsQuarterQ4 2025Date1/28/2026TimeBefore Market OpensConference Call DateWednesday, January 28, 2026Conference Call Time4:00PM ETUpcoming EarningsNurix Therapeutics' Q3 2026 earnings is estimated for Thursday, October 8, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Nurix Therapeutics Earnings HeadlinesNurix Therapeutics to Receive $7 Million Pfizer Collaboration Milestone Payment29 minutes ago | finance.yahoo.comNurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with PfizerSeptember 29 at 7:00 AM | globenewswire.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.September 29 at 1:00 AM | Stansberry Research (Ad)Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Has Average Price Target of $34.21September 28 at 2:28 AM | americanbankingnews.comNurix Therapeutics (NASDAQ:NRIX) Raised to Hold at Wall Street ZenSeptember 26 at 2:02 AM | americanbankingnews.comNurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference TranscriptSeptember 17, 2026 | seekingalpha.comSee More Nurix Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nurix Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nurix Therapeutics and other key companies, straight to your email. Email Address About Nurix TherapeuticsNurix Therapeutics (NASDAQ:NRIX) is a biopharmaceutical company focused on developing medicines that regulate the body’s natural protein-disposal systems to treat cancer and other serious diseases. The company’s approach centers on targeted protein modulation, including the use of small molecules to promote the degradation of disease-causing proteins or alter the activity of proteins involved in immune responses. Nurix’s technology platform is built around E3 ligases, enzymes that help determine which proteins are marked for destruction inside cells. Using this platform, the company develops targeted protein degraders and molecular glues designed to eliminate or modify selected proteins that may contribute to cancer. Its pipeline has included oral investigational therapies targeting proteins involved in B-cell malignancies and immune-cell regulation, including BTK and Cbl-b. The company’s research and development programs have included NX-5948, an orally administered BTK degrader being studied in B-cell cancers, and NX-1607, an investigational Cbl-b inhibitor intended to modulate immune-cell activity. Nurix has also pursued discovery and development collaborations with larger pharmaceutical companies, including Gilead Sciences, to apply its targeted protein degradation technology to additional therapeutic programs. Nurix Therapeutics was founded in 2009 and is headquartered in San Francisco, California. Its operations are primarily focused on drug discovery and clinical development, with programs intended for patients in international oncology and immunology markets. The company’s common stock trades on the Nasdaq under the symbol NRIX.View Nurix Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
